Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.40 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.40 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.39 |
| ▸ | FAAH | O00519 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.38 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3113604 | 0.99 | CNR2 (0.40) | CNR2ACKR3SMPD1MAPK14FAAH | |
| SCHEMBL3105246 | 0.96 | ACKR3 (0.41) | CNR2ACKR3MAPK14FAAHHPGD | |
| SCHEMBL3120854 | 0.96 | ACKR3 (0.41) | CNR2ACKR3MAPK14FAAHHPGD | |
| SCHEMBL3113338 | 0.93 | SMPD1 (0.43) | CNR2ACKR3SMPD1MAPK14FAAH | |
| SCHEMBL3112178 | 0.92 | ACKR3 (0.41) | CNR2ACKR3SMPD1MAPK14FAAH | |
| SCHEMBL3107180 | 0.92 | ACKR3 (0.41) | CNR2ACKR3SMPD1MAPK14FAAH | |
| SCHEMBL3110327 | 0.91 | ACKR3 (0.42) | CNR2ACKR3SMPD1MAPK14FAAH | |
| SCHEMBL5246436 | 0.90 | ACKR3 (0.44) | CNR2ACKR3MAPK14FAAHPLK1 | |
| SCHEMBL3110965 | 0.90 | ACKR3 (0.43) | CNR2ACKR3MAPK14HPGDBRD4 | |
| SCHEMBL3110302 | 0.89 | ACKR3 (0.43) | ACKR3MAPK14HPGDBRD4PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803822-B2 | Triazole derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-28 | — | — | US | disclosed |
| US-20090105253-A1 | Triazole Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-23 | — | — | US | disclosed |
| EP-1867331-A1 | TRIAZOLE DERIVATIVE AND THE USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105253-A1 | Triazole Derivative and Use Thereof | F2R, HRH4, F2RL3 | CNR2 39/4885ACKR3 122/4885SMPD1 4285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.